{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T18:30:09Z","timestamp":1785522609023,"version":"3.56.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:00:00Z","timestamp":1779235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:00:00Z","timestamp":1779235200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s12325-026-03548-w","type":"journal-article","created":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T07:47:48Z","timestamp":1779263268000},"page":"3488-3505","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Safety and Effectiveness of Guanfacine Hydrochloride Extended-Release in Adult Patients with ADHD in Japan: A Post-Marketing Surveillance Study"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4731-4886","authenticated-orcid":false,"given":"Akira","family":"Iwanami","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-2062-0377","authenticated-orcid":false,"given":"Katsuaki","family":"Shirai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2275-8344","authenticated-orcid":false,"given":"Hiroyuki","family":"Ida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,20]]},"reference":[{"issue":"1","key":"3548_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2015.20","volume":"1","author":"SV Faraone","year":"2015","unstructured":"Faraone SV, Asherson P, Banaschewski T, Biederman J, Buitelaar JK, Ramos-Quiroga JA, et al. Attention-deficit\/hyperactivity disorder. Nat Rev Dis Primers. 2015;1(1):15020. https:\/\/doi.org\/10.1038\/nrdp.2015.20.","journal-title":"Nat Rev Dis Primers"},{"key":"3548_CR2","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2024.1343314","author":"B French","year":"2024","unstructured":"French B, Nalbant G, Wright H, Sayal K, Daley D, Groom MJ, et al. The impacts associated with having ADHD: an umbrella review. Front Psychiatry. 2024. https:\/\/doi.org\/10.3389\/fpsyt.2024.1343314.","journal-title":"Front Psychiatry"},{"issue":"1","key":"3548_CR3","doi-asserted-by":"publisher","DOI":"10.1186\/1471-244X-10-67","volume":"10","author":"SJJ Kooij","year":"2010","unstructured":"Kooij SJJ, Bejerot S, Blackwell A, Caci H, Casas-Brugu\u00e9 M, Carpentier PJ, et al. European consensus statement on diagnosis and treatment of adult ADHD: the European Network Adult ADHD. BMC Psychiatry. 2010;10(1):67. https:\/\/doi.org\/10.1186\/1471-244X-10-67.","journal-title":"BMC Psychiatry"},{"issue":"3","key":"3548_CR4","first-page":"23591","volume":"16","author":"Y Ginsberg","year":"2014","unstructured":"Ginsberg Y, Quintero J, Anand E, Casillas M, Upadhyaya HP. Underdiagnosis of Attention-Deficit\/Hyperactivity Disorder in Adult Patients: A Review of the Literature. Primary Care Compan CNS Disorder. 2014;16(3):23591.","journal-title":"Primary Care Compan CNS Disorder"},{"key":"3548_CR5","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1016\/j.jad.2023.07.071","volume":"339","author":"G Ayano","year":"2023","unstructured":"Ayano G, Demelash S, Gizachew Y, Tsegay L, Alati R. The global prevalence of attention deficit hyperactivity disorder in children and adolescents: an umbrella review of meta-analyses. J Affect Disord. 2023;339:860\u20136. https:\/\/doi.org\/10.1016\/j.jad.2023.07.071.","journal-title":"J Affect Disord"},{"issue":"6","key":"3548_CR6","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1176\/ajp.2007.164.6.942","volume":"164","author":"G Polanczyk","year":"2007","unstructured":"Polanczyk G, de Lima MS, Horta BL, Biederman J, Rohde LA. The worldwide prevalence of ADHD: a systematic review and metaregression analysis. Am J Psychiatry. 2007;164(6):942\u20138. https:\/\/doi.org\/10.1176\/ajp.2007.164.6.942.","journal-title":"Am J Psychiatry"},{"issue":"3","key":"3548_CR7","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1192\/bjp.bp.107.048827","volume":"194","author":"V Simon","year":"2009","unstructured":"Simon V, Czobor P, B\u00e1lint S, M\u00e9sz\u00e1ros A, Bitter I. Prevalence and correlates of adult attention-deficit hyperactivity disorder: meta-analysis. Br J Psychiatry. 2009;194(3):204\u201311. https:\/\/doi.org\/10.1192\/bjp.bp.107.048827.","journal-title":"Br J Psychiatry"},{"issue":"5","key":"3548_CR8","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1192\/bjp.bp.106.034389","volume":"190","author":"J Fayyad","year":"2007","unstructured":"Fayyad J, De Graaf R, Kessler R, Alonso J, Angermeyer M, Demyttenaere K, et al. Cross-national prevalence and correlates of adult attention-deficit hyperactivity disorder. Br J Psychiatry. 2007;190(5):402\u20139. https:\/\/doi.org\/10.1192\/bjp.bp.106.034389.","journal-title":"Br J Psychiatry"},{"issue":"2","key":"3548_CR9","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s12402-014-0126-1","volume":"6","author":"M Fredriksen","year":"2014","unstructured":"Fredriksen M, Dahl AA, Martinsen EW, Klungsoyr O, Faraone SV, Peleikis DE. Childhood and persistent ADHD symptoms associated with educational failure and long-term occupational disability in adult ADHD. ADHD Atten Deficit Hyperact Disord. 2014;6(2):87\u201399. https:\/\/doi.org\/10.1007\/s12402-014-0126-1.","journal-title":"ADHD Atten Deficit Hyperact Disord"},{"issue":"2","key":"3548_CR10","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1177\/1087054708329777","volume":"13","author":"A Halm\u00f8y","year":"2009","unstructured":"Halm\u00f8y A, Fasmer OB, Gillberg C, Haavik J. Occupational outcome in adult ADHD: impact of symptom profile, comorbid psychiatric problems, and treatment: a cross-sectional study of 414 clinically diagnosed adult ADHD patients. J Atten Disord. 2009;13(2):175\u201387. https:\/\/doi.org\/10.1177\/1087054708329777.","journal-title":"J Atten Disord"},{"issue":"4","key":"3548_CR11","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1111\/1469-7610.00150","volume":"44","author":"K Minde","year":"2003","unstructured":"Minde K, Eakin L, Hechtman L, Ochs E, Bouffard R, Greenfield B, et al. The psychosocial functioning of children and spouses of adults with ADHD. J Child Psychol Psychiatry. 2003;44(4):637\u201346. https:\/\/doi.org\/10.1111\/1469-7610.00150.","journal-title":"J Child Psychol Psychiatry"},{"issue":"2","key":"3548_CR12","doi-asserted-by":"publisher","first-page":"131","DOI":"10.4306\/pi.2014.11.2.131","volume":"11","author":"JY Seo","year":"2014","unstructured":"Seo JY, Lee CS, Park CS, Kim BJ, Cha BS, Lee SJ, et al. Mediating effect of depressive symptoms on the relationship between adult attention deficit hyperactivity disorder and quality of life. Psychiatry Investig. 2014;11(2):131\u20136. https:\/\/doi.org\/10.4306\/pi.2014.11.2.131.","journal-title":"Psychiatry Investig"},{"issue":"3","key":"3548_CR13","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s12402-014-0150-1","volume":"6","author":"K Furczyk","year":"2014","unstructured":"Furczyk K, Thome J. Adult ADHD and suicide. Atten Defic Hyperact Disord. 2014;6(3):153\u20138. https:\/\/doi.org\/10.1007\/s12402-014-0150-1.","journal-title":"Atten Defic Hyperact Disord"},{"issue":"4","key":"3548_CR14","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1542\/peds.2012-2354","volume":"131","author":"WJ Barbaresi","year":"2013","unstructured":"Barbaresi WJ, Colligan RC, Weaver AL, Voigt RG, Killian JM, Katusic SK. Mortality, ADHD, and psychosocial adversity in adults with childhood ADHD: a prospective study. Pediatrics. 2013;131(4):637\u201344. https:\/\/doi.org\/10.1542\/peds.2012-2354.","journal-title":"Pediatrics"},{"issue":"12","key":"3548_CR15","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1177\/1087054715626511","volume":"23","author":"AJ Capusan","year":"2019","unstructured":"Capusan AJ, Bendtsen P, Marteinsdottir I, Larsson H. Comorbidity of adult ADHD and its subtypes with substance use disorder in a large population-based epidemiological study. J Atten Disord. 2019;23(12):1416\u201326. https:\/\/doi.org\/10.1177\/1087054715626511.","journal-title":"J Atten Disord"},{"issue":"6","key":"3548_CR16","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1177\/1087054715604360","volume":"22","author":"M Uchida","year":"2018","unstructured":"Uchida M, Spencer TJ, Faraone SV, Biederman J. Adult outcome of ADHD: an overview of results from the MGH longitudinal family studies of pediatrically and psychiatrically referred youth with and without ADHD of both sexes. J Atten Disord. 2018;22(6):523\u201334. https:\/\/doi.org\/10.1177\/1087054715604360.","journal-title":"J Atten Disord"},{"issue":"12","key":"3548_CR17","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1177\/1087054714529457","volume":"20","author":"JJ Rucklidge","year":"2016","unstructured":"Rucklidge JJ, Downs-Woolley M, Taylor M, Brown JA, Harrow SE. Psychiatric comorbidities in a New Zealand sample of adults with ADHD. J Atten Disord. 2016;20(12):1030\u20138. https:\/\/doi.org\/10.1177\/1087054714529457.","journal-title":"J Atten Disord"},{"key":"3548_CR18","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.2147\/dddt.S221126","volume":"15","author":"T Ota","year":"2021","unstructured":"Ota T, Yamamuro K, Okazaki K, Kishimoto T. Evaluating guanfacine hydrochloride in the treatment of attention deficit hyperactivity disorder (ADHD) in adult patients: design, development and place in therapy. Drug Des Devel Ther. 2021;15:1965\u20139. https:\/\/doi.org\/10.2147\/dddt.S221126.","journal-title":"Drug Des Devel Ther"},{"key":"3548_CR19","unstructured":"Pharmaceuticals and Medical Devices Agency (PMDA) (2023). Shionogi & Co., Ltd. Package Insert of Intuniv Tablets 1 mg \/ Intuniv Tablets 3 mg \u2013 Guanfacine Hydrochloride [in Japanese]. https:\/\/www.pmda.go.jp\/PmdaSearch\/iyakuDetail\/ResultDataSetPDF\/400256_1179057G1021_2_02"},{"issue":"3","key":"3548_CR20","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.19m12979","volume":"81","author":"A Iwanami","year":"2020","unstructured":"Iwanami A, Saito K, Fujiwara M, Okutsu D, Ichikawa H. Efficacy and safety of guanfacine extended-release in the treatment of attention-deficit\/hyperactivity disorder in adults: results of a randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2020;81(3):7891.","journal-title":"J Clin Psychiatry"},{"issue":"1","key":"3548_CR21","doi-asserted-by":"publisher","DOI":"10.1186\/s12888-020-02965-7","volume":"20","author":"A Iwanami","year":"2020","unstructured":"Iwanami A, Saito K, Fujiwara M, Okutsu D, Ichikawa H. Correction to: safety and efficacy of guanfacine extended-release in adults with attention-deficit\/hyperactivity disorder: an open-label, long-term, phase 3 extension study. BMC Psychiatry. 2020;20(1):596. https:\/\/doi.org\/10.1186\/s12888-020-02965-7.","journal-title":"BMC Psychiatry"},{"key":"3548_CR22","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.psychres.2015.12.017","volume":"236","author":"ME Butterfield","year":"2016","unstructured":"Butterfield ME, Saal J, Young B, Young JL. Supplementary guanfacine hydrochloride as a treatment of attention deficit hyperactivity disorder in adults: A double blind, placebo-controlled study. Psychiatr Res. 2016;236:136\u201341. https:\/\/doi.org\/10.1016\/j.psychres.2015.12.017.","journal-title":"Psychiatr Res"},{"key":"3548_CR23","unstructured":"\u82e5\u677e\u662d\u79c0, \u4eca\u4e95\u666f\u5b50, \u5ddd\u53c8\u5bdb\u548c, \u6709\u7530\u6075\u68a8\u5b50, \u77e2\u5cf6\u52c9, \u91ce\u53e3\u61b2\u4e00, \u5927\u897f\u9686, \u85e4\u91ce\u660e\u5b50. Methylphenidate\u5869\u9178\u5869\u5f90\u653e\u9320\u306e\u6210\u4eba\u6ce8\u610f\u6b20\u9665\u591a\u52d5\u6027\u969c\u5bb3\u60a3\u8005\u306b\u304a\u3051\u308b12\u30f5\u6708\u9593\u306e\u7279\u5b9a\u4f7f\u7528\u6210\u7e3e\u8abf\u67fb\u7d50\u679c [Results of the 12-month post marketing surveillance of extended-release tablet of methylphenidate in adult ADHD patients]. \u81e8\u5e8a\u7cbe\u795e\u85ac\u7406 [Japanese Journal of Clinical Psychopharmacology]. 2019;22(3):301\u201316."},{"key":"3548_CR24","unstructured":"\u5c71\u5d0e\u88d5\u7fa9, \u7af9\u7db1\u6b63\u5178, \u5409\u5ddd\u611b\u5b63, \u585a\u672c\u306f\u308b\u306a, \u4e2d\u6751\u667a\u5b9f. \u65e5\u5e38\u8a3a\u7642\u4e0b\u306b\u304a\u3051\u308b\u6210\u4eba\u671f\u306e\u6ce8\u610f\u6b20\u5982\/\u591a\u52d5\u6027\u969c\u5bb3\u306b\u5bfe\u3059\u308b\u30a2\u30c8\u30e2\u30ad\u30bb\u30c1\u30f3\u306e\u5b89\u5168\u6027\u304a\u3088\u3073\u6709\u52b9\u6027\u306e\u8a55\u4fa1-\u7279\u5b9a\u4f7f\u7528\u6210\u7e3e\u8abf\u67fb\u306e\u6700\u7d42\u89e3\u6790\u7d50\u679c- [Long-term safety and effectiveness of Atomoxetin for the treatment of Adult Attention-Deficit\/Hyperactivity Disorder (ADHD) in Routine Clinical Practice - Final results from Post-marketing Surveillance]. \u65b0\u85ac\u3068\u81e8\u7240 [Journal of New Remedies & Clinics]. 2018;67(2):110\u201324."},{"issue":"1","key":"3548_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-29252-3","volume":"15","author":"C \u00c7obano\u011flu Osmanl\u0131","year":"2025","unstructured":"\u00c7obano\u011flu Osmanl\u0131 C, Baykal S, \u00d6nal BS, \u015eahin B, Bozkurt A. Comprehensive analysis of guanfacine treatment in autism spectrum disorder with comorbid attention deficit hyperactivity disorder. Sci Rep. 2025;15(1):45310. https:\/\/doi.org\/10.1038\/s41598-025-29252-3.","journal-title":"Sci Rep"},{"issue":"1","key":"3548_CR26","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1089\/104454604773840481","volume":"14","author":"KA Stigler","year":"2004","unstructured":"Stigler KA, Desmond LA, Posey DJ, Wiegand RE, McDougle CJ. A naturalistic retrospective analysis of psychostimulants in pervasive developmental disorders. J Child Adolesc Psychopharmacol. 2004;14(1):49\u201356. https:\/\/doi.org\/10.1089\/104454604773840481.","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"11","key":"3548_CR27","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1016\/S2215-0366(23)00262-6","volume":"10","author":"T Pillinger","year":"2023","unstructured":"Pillinger T, Howes OD, Correll CU, Leucht S, Huhn M, Schneider-Thoma J, et al. Antidepressant and antipsychotic side-effects and personalised prescribing: a systematic review and digital tool development. Lancet Psychiatry. 2023;10(11):860\u201376. https:\/\/doi.org\/10.1016\/S2215-0366(23)00262-6.","journal-title":"Lancet Psychiatry"},{"issue":"4","key":"3548_CR28","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/s40675-023-00265-6","volume":"9","author":"LJ Klugherz","year":"2023","unstructured":"Klugherz LJ, Kolla BP, Mansukhani MP. Pharmacological treatments for insomnia. Curr Sleep Med Rep. 2023;9(4):265\u201373. https:\/\/doi.org\/10.1007\/s40675-023-00265-6.","journal-title":"Curr Sleep Med Rep"},{"issue":"2","key":"3548_CR29","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1089\/cap.2022.0038","volume":"33","author":"S Yu","year":"2023","unstructured":"Yu S, Shen S, Tao M. Guanfacine for the treatment of attention-deficit hyperactivity disorder: an updated systematic review and meta-analysis. J Child Adolesc Psychopharmacol. 2023;33(2):40\u201350. https:\/\/doi.org\/10.1089\/cap.2022.0038.","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"1","key":"3548_CR30","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1080\/14737175.2025.2599856","volume":"26","author":"MG Petruzzelli","year":"2026","unstructured":"Petruzzelli MG, Matera E, Margari L, Marzulli L, Gabellone A, Cotugno C, et al. An update on the comorbidity of attention deficit\/hyperactivity disorder (ADHD) and autism spectrum disorder (ASD) and its clinical management. Expert Rev Neurother. 2026;26(1):75\u201389. https:\/\/doi.org\/10.1080\/14737175.2025.2599856.","journal-title":"Expert Rev Neurother"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03548-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-026-03548-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03548-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T17:17:07Z","timestamp":1785518227000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-026-03548-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,20]]},"references-count":30,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["3548"],"URL":"https:\/\/doi.org\/10.1007\/s12325-026-03548-w","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,20]]},"assertion":[{"value":"29 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Akira Iwanami has no conflicts of interest to declare. Katsuaki Shirai and Hiroyuki Ida are employees of Takeda Pharmaceutical Co. Ltd.","order":1,"name":"Ethics","label":"Conflicts of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki and in compliance with the Ministerial Ordinance on Good Post-marketing Study Practice (GPSP) for drugs in Japan. In accordance with the GPSP Ordinance, institutional review board and ethics committee approvals were not required, as clinical treatment decisions, including the initiation of GXR, were made by the physician as part of routine care. The study was registered at the University Hospital Medical Information Network Clinical Trials Registry (identifier: UMIN000040429). Copyright licenses for the CGI-I scale, PGI-I scale, and the ADHD-RS-IV were obtained prior to their use in this study.\u00a0Patients provided written informed consent for the collection and use of their data in this study.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}